Merck & Co., Inc. (MRK) and The Competition Head to Head Analysis

Merck & Co., Inc. (NYSE:MRK – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Merck & Co., Inc. to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Merck & Co., Inc. and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merck & Co., Inc. 0 12 16 1 2.62
Merck & Co., Inc. Competitors 7859 13810 25854 1041 2.41

Merck & Co., Inc. currently has a consensus target price of $155.74, indicating a potential upside of 17.33%. As a group, “Pharmaceuticals” companies have a potential upside of 29.84%. Given Merck & Co., Inc.’s peers higher possible upside, analysts clearly believe Merck & Co., Inc. has less favorable growth aspects than its peers.

Profitability

This table compares Merck & Co., Inc. and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Merck & Co., Inc. 3.64% 16.73% 5.88%
Merck & Co., Inc. Competitors -2,391.72% -204.89% -14.89%

Dividends

Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.6%. Merck & Co., Inc. pays out 350.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.4% and pay out 48.0% of their earnings in the form of a dividend. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Merck & Co., Inc. lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.

Valuation & Earnings

This table compares Merck & Co., Inc. and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Merck & Co., Inc. $65.01 billion $18.25 billion 136.85
Merck & Co., Inc. Competitors $3.56 billion $3.18 billion 556.81

Merck & Co., Inc. has higher revenue and earnings than its peers. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Merck & Co., Inc.’s peers have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats its peers on 10 of the 15 factors compared.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.